Citigroup
JUNO

Citigroup’s Juno Therapeutics, Inc. JUNO Stock Holding History

Citigroup’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-55,100
Closed -$2.52M – 7815
2017
Q4 		$2.52M Sell
55,100
-46,900
-46% -$2.34M ﹤0.01% 2459
2017
Q3 		$4.58M Buy
102,000
+63,600
+166% +$2.17M ﹤0.01% 1855
2017
Q2 		$1.15M Buy
38,400
+7,700
+25% +$190K ﹤0.01% 3167
2017
Q1 		$681K Sell
30,700
-19,800
-39% -$425K ﹤0.01% 3604
2016
Q4 		$952K Buy
50,500
+12,800
+34% +$313K ﹤0.01% 3751
2016
Q3 		$1.13M Buy
37,700
+3,500
+10% +$109K ﹤0.01% 3089
2016
Q2 		$1.31M Buy
34,200
+11,900
+53% +$494K ﹤0.01% 2691
2016
Q1 		$849K Buy
22,300
+7,100
+47% +$247K ﹤0.01% 3530
2015
Q4 		$668K Sell
15,200
-83,600
-85% -$4.15M ﹤0.01% 3570
2015
Q3 		$4.02M Sell
98,800
-9,100
-8% -$399K ﹤0.01% 1846
2015
Q2 		$5.75M Buy
+107,900
New +$5.73M 0.01% 1623

Other funds holding JUNO

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Citigroup's JUNO Position: Q1 2018 in Review

Citigroup sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 83,438 shares — an estimated $3.81M sold.

Citigroup first reported a position in JUNO in Q1 2015 and held it in 12 quarters. The position peaked at $4.84M in Q4 2016. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

  • Citigroup reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Citigroup sold 83,438 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $3.81M.
  • Citigroup first reported a position in Juno Therapeutics, Inc. in Q1 2015 and held it in 12 quarters.
  • Citigroup's Juno Therapeutics, Inc. position peaked at $4.84M in Q4 2016.
  • 2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Citigroup's 13F filing for Q1 2018, filed 11 May 2018.